Berthrone Mock-Muhammad, MD
Cardiovascular Disease · Jackson, MSNPI 1285781153
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,080 of the $6,109 with a category attached, or 66.8%. 20 manufacturers reported payments, led by Cvrx, Inc. at 29.6% of the total. Reporting peaked in 2019 at $1,965 and has fallen 70.5% since, to $581 in 2025.
Across 103 payments — averaging $59.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$2K
- Boston Scientific$2K
- Boehringer Ingelheim$809
- Abbott$481
- Merck$278
- Abiomed$241
- plus $831 from 14 others
Across 10 payments — averaging $1592.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$16K
What the payments were for
- Travel & lodging$2,03033%
- Food & beverage$4,08067%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 13 | $1,806 |
| Boston Scientific | 10 | $1,664 |
| Boehringer Ingelheim | 18 | $809 |
| Abbott | 21 | $481 |
| Merck | 8 | $278 |
| Abiomed | 2 | $241 |
| AstraZeneca | 4 | $240 |
| Biotronik Inc. | 8 | $181 |
| Atricure, Inc. | 1 | $70 |
| Novo Nordisk | 3 | $59 |
| Amgen | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Kestra Medical Technology Services, Inc. | 1 | $42 |
| Braemar Manufacturing, LLC | 1 | $33 |
| Philips North America LLC | 1 | $30 |
| Johnson & Johnson | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Microport CRM USA Inc | 1 | $14 |
| Pfizer | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$1,583
- GENERAL - THERAPIES$1,536
- JARDIANCE$244
- Impella$241
- FARXIGA$125
How this compares
$6,109 in reported general payments places this provider in the 60th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 86 | $65,078 |
| EntrestoSacubitril/Valsartan | 56 | $55,273 |
| EliquisApixaban | 84 | $54,916 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,927 |
| Clonidine | 59 | $7,817 |
| BrilintaTicagrelor | 13 | $6,241 |
| LinzessLinaclotide | 12 | $6,097 |
| Ranolazine ErRanolazine | 60 | $3,605 |
| Metoprolol Succinate | 271 | $3,519 |
| Cilostazol | 153 | $2,822 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 41 | $2,707 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 31 | $2,607 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,513 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 35 | $2,467 |
| Nebivolol Hcl | 100 | $2,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $809 | $65,07886 claims |
| PfizerEliquis | $11 | $54,91684 claims |
| AstraZenecaBrilinta | $240 | $6,24113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.